A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor agonists for hidradenitis suppurativa (HS), with statistically significant reductions in HS-related scores at six months and at last follow-up.
This article was originally published on MedicalXpress.com